Skip to main content

Watson to Match Patients to Clinical Trials

IBM’s cognitive computer will be individualizing trial plans for cancer patients at the Mayo Clinic.

Written byBob Grant
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00

WIKIMEDIA, CLOCKREADYIBM’s Watson is one busy machine. Already deployed to aid researchers and clinicians at several institutions, the “cognitive computer” is now helping oncologists at the Mayo Clinic in Rochester, Minnesota, to sift through reams of patient records and sort individuals afflicted with cancer into appropriate clinical trials. “In an area like cancer, where time is of the essence, the speed and accuracy that Watson offers will allow us to develop an individualized treatment plan more efficiently so we can deliver exactly the care that the patient needs,” Steven Alberts, chair of medical oncology at Mayo Clinic, said in a statement.

Watson could ease the burden on clinical trial coordinators by matching thousands of patients, each with a unique health history and suite of symptoms, with thousands of experimental protocols that are designed to capture specific individuals. This should benefit not only patients, but the scientists who are running trials, said investigators at the Mayo Clinic. “With shorter times from initiation to completion of trials, our research teams will have the capacity for deeper, more complete investigations,” Nicholas LaRusso, a Mayo Clinic gastroenterologist and the project lead for the Mayo-IBM Watson collaboration, said in the statement. “Coupled with increased accuracy, we will be able to develop, refine and improve new and better techniques in medicine at a higher level.”

The computer, which will become more efficient ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?
Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Meet the Author

  • From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

    View Full Profile

Related Topics

Related articles background image
The Scientist Digest cover September 2026
September 2026

Multiplex Microscopy Becomes Easier with Encoded Antibodies

A new system that enables researchers to uniquely tag monoclonal antibodies for use in microscopy could help simplify complex imaging studies.

View this Issue
Essential Genes Are Dominantly Activated by Single Transcription Factors

Essential Genes Are Dominantly Activated by Single Transcription Factors

EpiCypher Logo
Rethinking ALS Biomarkers: From Discovery to Clinical Impact

Rethinking ALS Biomarkers: From Discovery to Clinical Impact

Alamar Biosciences logo
Engineering CAR-Neutrophils In Vivo to Target Glioblastoma

Engineering CAR-Neutrophils In Vivo to Target Glioblastoma

Miltenyi
Best Practices for qPCR Assay Design and Optimization

Best Practices for qPCR Assay Design and Optimization

Bio-Rad

Products

Closeup image of a multi channel pipette dispensing pink liquid into a 96-well plate.

The ASSIST PLUS pipetting robot for affordable workflow automation

Integra Logo
Single cells in suspension

Rapidly isolate primary cells and make uniform single-cell suspensions with Corning® Cell Strainers

Corning logo
Abstract image representing cell membranes linked together.

CellBrite® Steady Membrane Stain: Cell surface staining built for real-time imaging

Biotium
sino biological logo

Monod Bio Licenses AI-designed Protein Technologies to SignalChem Biotech for Custom Discovery Assays